Related references
Note: Only part of the references are listed.Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using 68Ga-DOTATOC and 68Ga-DOTATATE
Ezgi Ilan et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors
Harun Ilhan et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Automated GMP compliant production of [18F]AlF-NOTA-octreotide
Terence Tshibangu et al.
EJNMMI RADIOPHARMACY AND CHEMISTRY (2020)
Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms
Tingting Long et al.
CLINICAL NUCLEAR MEDICINE (2019)
Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient
Elin Pauwels et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Thomas A. Hope et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
Martin H. Cherk et al.
CANCER IMAGING (2018)
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA
Murat Fani Bozkurt et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Somatostatin Receptor 2-Targeting Compounds
Daan A. Smit Duijzentkunst et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours
S. Van Binnebeek et al.
EUROPEAN RADIOLOGY (2016)
Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites
Samira M. Sadowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors
Suraiya R. Dubash et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
Stephen A. Deppen et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients Correlation of parameters during PRRT
Sofie Van Binnebeek et al.
NUKLEARMEDIZIN-NUCLEAR MEDICINE (2016)
Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors
Mattias Sandstrom et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Optimized labeling of NOTA-conjugated octreotide with F-18
Peter Laverman et al.
TUMOR BIOLOGY (2012)
Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
Alexander R. Haug et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Comparison of receptor affinity of Sc-nat-DOTA-TATE versus Ga-nat-DOTA-TATE
Eftychia Koumarianou et al.
NUCLEAR MEDICINE REVIEW (2011)
A Novel Facile Method of Labeling Octreotide with 18F-Fluorine
Peter Laverman et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
In vivo binding of [Ga-68]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass
Irina Velikyan et al.
NUCLEAR MEDICINE AND BIOLOGY (2010)
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:: Comparison with somatostatin receptor scintigraphy and CT
Michael Gabriel et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Share Paper
